Baxter Enters Agreement to Sell Vero Cell Vaccines Platform
Baxter announced that it had entered into an agreement to sell its Vero cell technology and related assets to Nanotherapeutics.
Baxter International announced on Dec. 15, 2014 that it had entered into an agreement with Nanotherapeutics to divest Vero cell technology, related assets, and its production facility in Bohumil, Czech Republic. The assets divested as part of the agreement include the vaccines for H5N1, H1N1, the seasonal flu, and investigational vaccines for Ross River virus, Chikungunya disease, and West Nile virus. Vero cell platform is a cell-based technology for vaccine production.
"The divestiture of the vaccines franchise will allow Baxter BioScience to enhance focus in core therapeutic areas of hematology, oncology, and immunology, as it prepares to become an independent biopharmaceutical company,” said Ludwig Hantson, PhD, president of Baxter BioScience, in a press release.
Source: Baxter
Telix Enters Agreement with ImaginAb to Purchase Next-Gen Therapeutic Candidates
Published: January 13th 2025 | Updated: January 13th 2025The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
